Developer docs
API playgroundTry for free, no card

Search company profiles

Island Pharmaceuticals

Full company profile

uuid0032698

Namestring
Island Pharmaceuticals
Legal namestring
Island Pharmaceuticals Limited
Company typeenum
Public
Founded yearint
2021
Descriptiontext

Island Pharmaceuticals Limited (ASX: ILA) is a clinical-stage Australian antiviral therapeutics company that develops and repurposes small-molecule drugs for infectious diseases with limited or no approved treatment options. The company is headquartered in Camberwell, Victoria, and has operated with a headcount of 1-10 employees since its oversubscribed IPO on the Australian Securities Exchange in April 2021.

The company's pipeline comprises two core assets. ISLA-101 is an antiviral compound being repurposed for dengue fever and other mosquito-borne flavivirus infections, supported by patents granted in the US, Australia, Canada, and Brazil (with US IP extending through 2042 for COVID-19 use), and has progressed through a successful Phase 2a readout and Phase 2b enrollment. Galidesivir was acquired from BioCryst in July 2025 and is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway, with FDA Orphan Drug Designation and Tropical Disease Priority Review Voucher eligibility confirmed; a three-year CRADA with USAMRIID and The Geneva Foundation, plus a Master Service Agreement with Texas Biomedical Research Institute for BSL-4 non-human primate studies, support the development program.

Island is pre-revenue and does not yet commercialize any product. Its go-to-market model is dual-track: an endemic commercial path for ISLA-101 through standard pharmaceutical development and regulatory approval, and a US government biodefense procurement path for Galidesivir targeting the Department of Defense and Health and Human Services, with Priority Review Voucher monetization as an additional value lever. Revenue mechanics are therefore expected to combine eventual product sales, government stockpiling contracts, and potential licensing or PRV transactions. Capital is sourced primarily through ASX-listed equity placements, rights issues, and a US government grant, with a stated A$9 million placement in February 2026 explicitly dedicated to financing the Galidesivir program.

Short descriptiontext

Island Pharmaceuticals is an Australian clinical-stage antiviral biotech (ASX: ILA) repurposing small-molecule drugs for dengue fever (ISLA-101) and developing Galidesivir for Marburg virus under the FDA Animal Rule pathway for US biodefense procurement.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCamberwell, Australia
HQ citystring
Camberwell
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antiviral therapeutics, dengue fever treatment, drug repurposing, biodefense antivirals, infectious disease drugs
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antiviral Therapeutics
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Island Pharmaceuticals is a clinical-stage biotech company that does not yet have commercialized products. The company is developing ISLA-101 for dengue fever and Galidesivir for Marburg virus. Revenue will come from product sales pending regulatory approvals.

islandpharmaceuticals.com
2Government Procurement
TypeLicensing Royalties
Description

The company targets US government procurement and stockpiling of Galidesivir as a biodefense countermeasure, with potential Priority Review Voucher eligibility upon approval.

smallcaps.com.au
3Priority Review Voucher
TypeLicensing Royalties
Description

Upon FDA approval of Galidesivir for tropical diseases like Marburg virus, the company may be eligible for a Tropical Disease Priority Review Voucher which can be sold to other pharmaceutical companies.

tipranks.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Island Pharmaceuticals is a clinical-stage antiviral therapeutics company developing and repurposing drug candidates for infectious diseases. Its lead asset ISLA-101 is being developed as a treatment for dengue fever and other mosquito-borne flavivirus infections, while Galidesivir is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway for biodefense applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2a clinical trial achieved endpoints in dengue fever patients
+2 more records
Product overview1 text field

Island Pharmaceuticals is an antiviral therapeutics company with two core drug candidates: ISLA-101 and Galidesivir. ISLA-101 is being developed for dengue fever and other mosquito-borne diseases (flaviviruses), having successfully completed Phase 2a trials. Galidesivir is being developed for biodefense applications targeting Marburg virus under FDA Animal Rule pathway. The company focuses on drug repurposing strategies to accelerate development of treatments for unmet needs in infectious diseases.

Product and service1 record
1ISLA-101
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Three-year Cooperative Research and Development Agreement (CRADA) with USAMRIID and The Geneva Foundation to advance Galidesivir for Marburg Virus Disease under the FDA Animal Rule pathway. Non-human primate studies are planned as key steps toward New Drug Application approval.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-03
Description

Partnering with USAMRIID under the three-year CRADA to advance Galidesivir development. The Geneva Foundation supports military medical research and provides access to specialized research capabilities.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-17
Description

Master Service Agreement with Texas Biomedical for antiviral drug development. Texas Biomed provides BSL-4 (Biosafety Level 4) laboratory capabilities for non-human primate studies required for Galidesivir development under the FDA Animal Rule pathway.

4Medical Countermeasures Coalition
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-17
Description

Island Pharmaceuticals joined the Medical Countermeasures Coalition, which advances US government procurement and stockpiling of medical countermeasures. Coalition membership supports the company's pathway to potential US government procurement for Galidesivir.

tipranks.com
5Galidesivir Acquisition from BioCryst
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-07-09
Description

Island Pharmaceuticals completed the acquisition of Galidesivir from BioCryst, expanding its antiviral portfolio. This transaction brought the Marburg virus asset into Island's pipeline.

islandpharmaceuticals.com
Strategic tierSupportingTypeGTM or Marketing PartnerAnnounced on2025-01-26
Description

Appointed a Washington-based policy advisor to advance US government engagement and navigate regulatory pathways for the Galidesivir biodefense program.

Strategic tierSupportingTypeTechnology or Integration
Description

Anti-Viral Molecule Screening Collaboration with Griffith University for screening of antiviral compounds.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

European biodefense and infectious disease vaccine/antiviral company with FDA-approved JYNNEOS smallpox vaccine and significant BARDA contracts. Larger established player in the same medical countermeasures space Island is targeting with Galidesivir.

TypeEmerging player
Description

Clinical-stage antiviral developer that has historically pursued dengue and other flavivirus therapeutics, providing a direct comparable in the dengue antiviral development pathway that Island is following with ISLA-101.

TypeDirect peer
Description

Originally developed Galidesivir before divesting it to Island Pharmaceuticals. BioCryst is a US clinical/commercial antiviral company focused on rare disease antivirals (Rapivab, Orladeyo), making it the most direct prior owner and developer of Island's lead biodefense asset.

TypeEmerging player
Description

Clinical-stage biotech with dengue vaccine (Phase 2) and self-amplifying mRNA platform. Similar profile to Island as a small-cap antiviral/infectious disease developer targeting dengue with regulatory pathway validation.

TypeBroad incumbent
Description

Developing mRNA-based dengue vaccine candidates through Phase 3 trials and has broad infectious disease vaccine capabilities. Represents the competitive vaccine landscape that ISLA-101 (an antiviral) would need to complement or compete against.

TypeBroad incumbent
Description

Vaccine developer with approved products for COVID-19 and R21/Matrix-M malaria vaccine (dengue-adjacent). Larger infectious disease vaccine player that overlaps with the flavivirus therapeutic and biodefense space where Island operates.

TypeBroad incumbent
Description

Larger biodefense and specialty pharma incumbent that supplies medical countermeasures to US government (anthrax vaccines, smallpox, NARCAN). Comparable business model of pursuing FDA Animal Rule approvals and government procurement contracts, though at much greater scale.

TypeDirect peer
Description

Small-cap US antiviral company focused on rare/orphan infectious diseases, including work on filoviruses and biodefense indications. Direct comparable in size, clinical-stage profile, and antiviral pipeline focus.

TypeBroad incumbent
Description

Owns QDENGA, the leading approved dengue vaccine, and has deep dengue commercial infrastructure across endemic regions. While not a direct antiviral peer, Takeda represents the dominant commercial competitor for any dengue therapeutic seeking market access.

TypeDirect peer
Description

US biodefense-focused pharma with TPOXX (tecovirimat) approved for smallpox via the FDA Animal Rule. Direct comparable for Island's Galidesivir strategy of pursuing Animal Rule approval for filovirus/orthopoxvirus countermeasures with US government stockpiling.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Island Pharmaceuticals

Antiviral Therapeuticsislandpharmaceuticals.com

Island Pharmaceuticals is an Australian clinical-stage antiviral biotech (ASX: ILA) repurposing small-molecule drugs for dengue fever (ISLA-101) and developing Galidesivir for Marburg virus under the FDA Animal Rule pathway for US biodefense procurement.

What Island Pharmaceuticals does

Island Pharmaceuticals Limited (ASX: ILA) is a clinical-stage Australian antiviral therapeutics company that develops and repurposes small-molecule drugs for infectious diseases with limited or no approved treatment options. The company is headquartered in Camberwell, Victoria, and has operated with a headcount of 1-10 employees since its oversubscribed IPO on the Australian Securities Exchange in April 2021.

The company's pipeline comprises two core assets. ISLA-101 is an antiviral compound being repurposed for dengue fever and other mosquito-borne flavivirus infections, supported by patents granted in the US, Australia, Canada, and Brazil (with US IP extending through 2042 for COVID-19 use), and has progressed through a successful Phase 2a readout and Phase 2b enrollment. Galidesivir was acquired from BioCryst in July 2025 and is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway, with FDA Orphan Drug Designation and Tropical Disease Priority Review Voucher eligibility confirmed; a three-year CRADA with USAMRIID and The Geneva Foundation, plus a Master Service Agreement with Texas Biomedical Research Institute for BSL-4 non-human primate studies, support the development program.

Island is pre-revenue and does not yet commercialize any product. Its go-to-market model is dual-track: an endemic commercial path for ISLA-101 through standard pharmaceutical development and regulatory approval, and a US government biodefense procurement path for Galidesivir targeting the Department of Defense and Health and Human Services, with Priority Review Voucher monetization as an additional value lever. Revenue mechanics are therefore expected to combine eventual product sales, government stockpiling contracts, and potential licensing or PRV transactions. Capital is sourced primarily through ASX-listed equity placements, rights issues, and a US government grant, with a stated A$9 million placement in February 2026 explicitly dedicated to financing the Galidesivir program.

Island Pharmaceuticals firmographics

Firmographics
Name
Island Pharmaceuticals
Legal name
Island Pharmaceuticals Limited
Website
https://islandpharmaceuticals.com
Company type
Public
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Island Pharmaceuticals is an Australian clinical-stage antiviral biotech (ASX: ILA) repurposing small-molecule drugs for dengue fever (ISLA-101) and developing Galidesivir for Marburg virus under the FDA Animal Rule pathway for US biodefense procurement.
Ownership category
akta.pro rank

Island Pharmaceuticals industry classification

Industry
Product category
Antiviral Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antiviral therapeutics
  • Dengue fever treatment
  • Drug repurposing
  • Biodefense antivirals
  • Infectious disease drugs

Where Island Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Camberwell
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Island Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Island Pharmaceuticals is a clinical-stage biotech company that does not yet have commercialized products. The company is developing ISLA-101 for dengue fever and Galidesivir for Marburg virus. Revenue will come from product sales pending regulatory approvals.
  2. Government Procurement: The company targets US government procurement and stockpiling of Galidesivir as a biodefense countermeasure, with potential Priority Review Voucher eligibility upon approval.
  3. Priority Review Voucher: Upon FDA approval of Galidesivir for tropical diseases like Marburg virus, the company may be eligible for a Tropical Disease Priority Review Voucher which can be sold to other pharmaceutical companies.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Island Pharmaceuticals product offering

Product offering

Core offering

Island Pharmaceuticals is a clinical-stage antiviral therapeutics company developing and repurposing drug candidates for infectious diseases. Its lead asset ISLA-101 is being developed as a treatment for dengue fever and other mosquito-borne flavivirus infections, while Galidesivir is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway for biodefense applications.

Product overview

Island Pharmaceuticals is an antiviral therapeutics company with two core drug candidates: ISLA-101 and Galidesivir. ISLA-101 is being developed for dengue fever and other mosquito-borne diseases (flaviviruses), having successfully completed Phase 2a trials. Galidesivir is being developed for biodefense applications targeting Marburg virus under FDA Animal Rule pathway. The company focuses on drug repurposing strategies to accelerate development of treatments for unmet needs in infectious diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • ISLA-101

Quantifiable outcome

  • Phase 2a clinical trial achieved endpoints in dengue fever patients
  • +2 more outcomes

Companies that use Island Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles2 records

Island Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Island Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, major and supporting.

  • USAMRIID (United States Army Medical Research Institute of Infectious Diseases)coreStrategic or Co-development Partner · 3 March 2026Three-year Cooperative Research and Development Agreement (CRADA) with USAMRIID and The Geneva Foundation to advance Galidesivir for Marburg Virus Disease under the FDA Animal Rule pathway. Non-human primate studies are planned as key steps toward New Drug Application approval.
  • The Geneva FoundationcoreStrategic or Co-development Partner · 3 March 2026Partnering with USAMRIID under the three-year CRADA to advance Galidesivir development. The Geneva Foundation supports military medical research and provides access to specialized research capabilities.
  • Texas Biomedical Research InstitutecoreTechnology or Integration · 17 December 2025Master Service Agreement with Texas Biomedical for antiviral drug development. Texas Biomed provides BSL-4 (Biosafety Level 4) laboratory capabilities for non-human primate studies required for Galidesivir development under the FDA Animal Rule pathway.
  • Medical Countermeasures CoalitionmajorStrategic or Co-development Partner · 17 November 2025Island Pharmaceuticals joined the Medical Countermeasures Coalition, which advances US government procurement and stockpiling of medical countermeasures. Coalition membership supports the company's pathway to potential US government procurement for Galidesivir.
  • Galidesivir Acquisition from BioCrystcoreOEM/ Whitelabel/ Licensing Partner · 9 July 2025Island Pharmaceuticals completed the acquisition of Galidesivir from BioCryst, expanding its antiviral portfolio. This transaction brought the Marburg virus asset into Island's pipeline.
  • Washington-based Policy AdvisorsupportingGTM or Marketing Partner · 26 January 2025Appointed a Washington-based policy advisor to advance US government engagement and navigate regulatory pathways for the Galidesivir biodefense program.
  • Griffith UniversitysupportingTechnology or IntegrationAnti-Viral Molecule Screening Collaboration with Griffith University for screening of antiviral compounds.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Island Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Bavarian Nordic: European biodefense and infectious disease vaccine/antiviral company with FDA-approved JYNNEOS smallpox vaccine and significant BARDA contracts. Larger established player in the same medical countermeasures space Island is targeting with Galidesivir.
  • Moderna: Developing mRNA-based dengue vaccine candidates through Phase 3 trials and has broad infectious disease vaccine capabilities. Represents the competitive vaccine landscape that ISLA-101 (an antiviral) would need to complement or compete against.
  • Novavax: Vaccine developer with approved products for COVID-19 and R21/Matrix-M malaria vaccine (dengue-adjacent). Larger infectious disease vaccine player that overlaps with the flavivirus therapeutic and biodefense space where Island operates.
  • Emergent BioSolutions: Larger biodefense and specialty pharma incumbent that supplies medical countermeasures to US government (anthrax vaccines, smallpox, NARCAN). Comparable business model of pursuing FDA Animal Rule approvals and government procurement contracts, though at much greater scale.
  • Takeda Pharmaceutical: Owns QDENGA, the leading approved dengue vaccine, and has deep dengue commercial infrastructure across endemic regions. While not a direct antiviral peer, Takeda represents the dominant commercial competitor for any dengue therapeutic seeking market access.

Emerging players

  • Atea Pharmaceuticals: Clinical-stage antiviral developer that has historically pursued dengue and other flavivirus therapeutics, providing a direct comparable in the dengue antiviral development pathway that Island is following with ISLA-101.
  • Arcturus Therapeutics: Clinical-stage biotech with dengue vaccine (Phase 2) and self-amplifying mRNA platform. Similar profile to Island as a small-cap antiviral/infectious disease developer targeting dengue with regulatory pathway validation.

Direct peers

  • BioCryst Pharmaceuticals: Originally developed Galidesivir before divesting it to Island Pharmaceuticals. BioCryst is a US clinical/commercial antiviral company focused on rare disease antivirals (Rapivab, Orladeyo), making it the most direct prior owner and developer of Island's lead biodefense asset.
  • Chimerix: Small-cap US antiviral company focused on rare/orphan infectious diseases, including work on filoviruses and biodefense indications. Direct comparable in size, clinical-stage profile, and antiviral pipeline focus.
  • SIGA Technologies: US biodefense-focused pharma with TPOXX (tecovirimat) approved for smallpox via the FDA Animal Rule. Direct comparable for Island's Galidesivir strategy of pursuing Animal Rule approval for filovirus/orthopoxvirus countermeasures with US government stockpiling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Island Pharmaceuticals social profiles

Digital presence

Island Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Island Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Island Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Island Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Island Pharmaceuticals

What does Island Pharmaceuticals do?

Island Pharmaceuticals is a clinical-stage antiviral therapeutics company developing and repurposing drug candidates for infectious diseases. Its lead asset ISLA-101 is being developed as a treatment for dengue fever and other mosquito-borne flavivirus infections, while Galidesivir is being advanced for Marburg Virus Disease under the FDA Animal Rule pathway for biodefense applications.

Is Island Pharmaceuticals a public or private company?

Island Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Island Pharmaceuticals founded?

Island Pharmaceuticals was founded in 2021. It employs 1 to 10 people.

Where is Island Pharmaceuticals based?

Island Pharmaceuticals is headquartered in Camberwell, Australia, in the Oceania region.

How does Island Pharmaceuticals make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are government Procurement and priority Review Voucher.

Who are Island Pharmaceuticals's main competitors?

Broad incumbents on record are Bavarian Nordic, Moderna, Novavax, Emergent BioSolutions and Takeda Pharmaceutical. Emerging players are Atea Pharmaceuticals and Arcturus Therapeutics. Direct peers are BioCryst Pharmaceuticals, Chimerix and SIGA Technologies.

Does Island Pharmaceuticals have an API?

No public API is recorded for Island Pharmaceuticals.

What industry is Island Pharmaceuticals in?

Island Pharmaceuticals's product category is Antiviral Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaIsland Pharmaceuticals Limited (ILPLF) Shareholder/Analyst Call TranscriptIsland Pharmaceuticals CEO David Foster and Chairman Jason Carroll discussed progress on Galidesivir studies in a November 16, 2026 webinar. The company is entering a critical period with studies that could materially advance the regulatory pathway. No specific milestones or data were disclosed.The AustralianIsland has almost 250% upside to valuationRaaS Research Group maintained a $1.60 per share valuation for Island Pharmaceuticals, implying 248% upside from its 46-cent price. The company's second manufacturing campaign for Galidesivir will increase inventory to 700-800 treatment courses in Q4 CY26 for the Bundibugyo Ebola outbreak. Island expects deployment in Uganda during 2026.TradingViewIsland Pharmaceuticals Builds Galidesivir Inventory for Outbreak ResponseIsland Pharmaceuticals commissioned a second Galidesivir manufacturing campaign with PI Health Sciences to expand its outbreak-response inventory. The run is expected to lift supply to about 700-800 treatment courses by Q4 2026, supporting the Bundibugyo Ebola outbreak in Uganda, which has 5,208 cases and 2,476 deaths.Biotech DispatchIsland Pharmaceuticals begins GMP manufacture of Galidesivir to support pivotal Marburg studyIsland Pharmaceuticals has commenced Good Manufacturing Practice (GMP) production of its antiviral drug Galidesivir in partnership with PI Health Sciences to support a pivotal Marburg virus study. This manufacturing campaign aims to secure the clinical-grade material necessary for future FDA submission under the Animal Rule pathway, while existing inventory will be utilized for dose optimization studies.MarketScreenerIsland Pharmaceuticals Signs Statement of Work With Texas Biomed to Advance Galidesivir, Shares Hit Six Month HighIsland Pharmaceuticals has signed a Statement of Work with Texas Biomed to advance the development of Galidesivir, an antiviral drug candidate. The company's shares responded by hitting a six-month high on the news of the partnership. Island Pharmaceuticals is an Australia-based drug repurposing company focused on antiviral therapeutics for infectious diseases, with operations spanning Australia and the United States.AInvestIsland Pharmaceuticals Ltd-Texas Biomed SOW accelerates pivotal FDA pathwayIsland Pharmaceuticals Ltd has signed a Master Service Agreement with Texas Biomedical Research Institute to advance its antiviral candidate Galidesivir through the FDA's Animal Rule pathway, which allows approval based on animal studies when human trials are not feasible. The FDA has confirmed Galidesivir's eligibility for this pathway and its potential qualification for a Priority Review Voucher upon approval. The company expects further FDA guidance by early January 2026, with a planned clinical program in Q1 2026 pending regulatory approval.BioWorldIsland Pharma targets Ebola species lacking approved treatmentsIsland Pharma secured government and ethics approvals to deploy its investigational antiviral galidesivir in patients infected during the Bundibugyo Ebola outbreak in Africa. The Australian biotech aims to collect prospective human data in an active filovirus emergency.BloombergIsland Pharma Jumps After Emergency-Use Approval for Ebola DrugAustralia's Island Pharmaceuticals Ltd. received regulatory and ethics approvals for emergency use of its experimental antiviral drug galidesivir in Uganda for patients with the Bundibugyo strain of Ebola. The company's stock surged as much as 47% following the announcement, trading 30% higher at A$0.48, with earlier peaks reaching A$0.55 — the highest intraday price since December 2025. The intravenous drug, designed to block viral replication, is expected to become available later this year under a World Health Organization emergency-use program.INNGovernment approvals secured for the use of Galidesivir as a treatment for Bundibugyo Ebola epidemic in AfricaAustralian antiviral drug development company Island Pharmaceuticals Ltd has secured all regulatory and ethics approvals from Uganda's government authorities to enable compassionate use of Galidesivir for treating patients infected during the ongoing Bundibugyo Ebola virus outbreak. The outbreak has caused 1,481 confirmed cases and 454 deaths across multiple African countries including Uganda and the Democratic Republic of Congo, with a rising case fatality rate of 31% and no approved therapeutic options currently available. The approval allows deployment under the WHO-recognized MEURI framework, enabling prospective human clinical data collection while providing an investigational treatment option in this public health emergency.TipranksIsland Pharmaceuticals Secures Key FDA Boost and US Partnerships for Galidesivir Antiviral ProgramIsland Pharmaceuticals Ltd reported substantial progress in Q4 2025 for its Galidesivir antiviral program, including FDA confirmation that the drug qualifies for Animal Rule approval against Marburg virus and is eligible for a Tropical Disease Priority Review Voucher upon approval. The company also executed a Master Service Agreement with Texas Biomedical Research Institute for BSL-4 non-human primate studies, appointed a Washington-based policy advisor, joined the Medical Countermeasures Coalition, and extended US intellectual property protection for COVID-19 use through 2042.